Ornidazole Infusion
| Product/Composition:- | Ornidazole Infusion |
|---|---|
| Strength:- | 100ml |
| Form:- | Infusion |
| Production Capacity | 1 Million Infusion/Month |
| Therapeutic use:- | Fluid Therapy |
| Package Insert/Leaflet: | Available upon request |
Give a supplemental dose (50% of the usual dose) before dialysis.Double the interval between doses.Renal and hepatic impairment. CNS diseases e.g. epilepsy or multiple sclerosis. May impair ability to drive or operate machinery.
Pregnancy and lactation.Somnolence, headache, nausea, vomiting, dizziness, tremor, rigidity, poor coordination, seizures, tiredness, vertigo, temporary loss of consciousness and signs of sensory or mixed peripheral neuropathy, taste disturbances, abnormal LFTs, skin reactions.Potentiates effect of coumarin-type oral anticoagulants. Prolongs the muscle-relaxant effect of vecuronium bromide. See Below for More ornidazole Drug Interactions.Ornidazole is a 5-nitroimidazole derivative active against protozoa and anaerobic bacteria. It is converted to reduction products that interact with DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms.Readily absorbed (oral and intravaginal); peak plasma concentrations after 2 hr (oral), 12 hr (intravaginal).Body tissues and fluids (wide), CSF. Protein-binding: <15%.Via urine (as conjugates and metabolites), via faeces (small amounts); 12-14 hr (elimination half-life).